ALLO logo

Allogene Therapeutics Inc. (ALLO)

$0.74

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ALLO

Market cap

$257806323

EPS

-0.63

P/E ratio

--

Price to sales

108.71

Dividend yield

--

Beta

0.766607

Price on ALLO

Previous close

$0.81

Today's open

$0.80

Day's range

$0.74 - $0.82

52 week range

$0.74 - $4.46

Profile about ALLO

CEO

David Chang

Employees

152

Headquarters

South San Francisco, CA

Exchange

Nasdaq Global Select

Shares outstanding

346467307

Issue type

Common Stock

ALLO industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ALLO

Allogene Therapeutics, Inc. (ALLO) Presents at UBS Global Biopharma Conference 2026 Transcript

Allogene Therapeutics, Inc. (ALLO) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 16, 2026

news preview

Allogene Therapeutics, Inc. (ALLO) Reviews Preliminary ALLO-329 Safety and Efficacy Data in Autoimmune Diseases Transcript

Allogene Therapeutics, Inc. ( ALLO ) Reviews Preliminary ALLO-329 Safety and Efficacy Data in Autoimmune Diseases November 9, 2026 9:00 AM EST Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer Zachary Roberts - President, CEO & Director Conference Call Participants Vivek Nagaraja Biren Amin - Piper Sandler & Co., Research Division Tyler Van Buren - TD Cowen, Research Division John Newman - Canaccord Genuity Corp., Research Division Cha Cha Yang - Jefferies LLC, Research Division Presentation Operator Hello. Thank you for standing by, and welcome to Allogene Therapeutics Conference Call.

news source

Seeking Alpha • Nov 9, 2026

news preview

Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced preliminary safety, efficacy and translational data from the ongoing Phase 1 RESOLUTION study evaluating ALLO-329, an investigational, next-generation, off-the-shelf allogeneic CAR T product designed specifically for autoimmune disease. The data are being presented today at the American College of Rheumatology (ACR) Convergence in Orlando, Florida.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Allogene Therapeutics, Inc. (ALLO) Q3 2026 Earnings Call Transcript

Allogene Therapeutics, Inc. ( ALLO ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer Zachary Roberts - President, CEO & Director Geoffrey Parker Conference Call Participants Tyler Van Buren - TD Cowen, Research Division Michael Yee - UBS Investment Bank, Research Division Jiale Song - Jefferies LLC, Research Division Samantha Semenkow - Citigroup Inc., Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Jack Allen - Robert W.

news source

Seeking Alpha • Nov 6, 2026

news preview

Allogene Therapeutics Q3 Earnings Call Highlights

Allogene Therapeutics NASDAQ: ALLO expects to complete enrollment in its ALPHA3 lymphoma trial by the end of 2027, as increased screening and activity in Asia-Pacific help support recruitment, executives said on the company's third-quarter earnings call.

news source

MarketBeat • Nov 6, 2026

news preview

Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 5, 2026

news preview

Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced its participation in the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Phoenix, Arizona. The Company's participation includes two invited presentations and a preclinical poster showcasing the breadth and continued evolution of its platform.

news source

GlobeNewsWire • Nov 3, 2026

news preview

Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced two November investor events highlighting third quarter 2026 results and the first clinical update from its ALLO-329 autoimmune disease program.

news source

GlobeNewsWire • Oct 29, 2026

news preview

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conferences in November and December 2026.

news source

GlobeNewsWire • Oct 26, 2026

news preview

Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

news source

Zacks Investment Research • Sep 11, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Allogene Therapeutics Inc.

Open an M1 investment account to buy and sell Allogene Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ALLO on M1